Clene’s CNM-Au8® Shows Statistically Significant Difference in Plasma Neurofilament Light (NfL) levels in the HEALEY ALS Platform Trial
· CNM-Au8^® treatment demonstrated significantly reduced plasma neurofilament light chain (NfL) levels compared to placebo at 24..
GlobeNewswire